Document is current
Any future updates will be listed below
-
Authors
Qin, Shukui
Bai, Yuxian
Li, Jin
Pan, Hongming
Luo, Suxia
Qu, Yanli
Ye, Feng
Yang, Lin
Liu, Tianshu
Li, Wei
Chen, Xi
Yang, Jianwei
Ying, Jieer
Lin, Xiaoyan
Zhao, Lin
Liang, Xinjun
Mao, Yixiang
Guo, Run https://orcid.org/0009-0001-3594-2642
Zuo, Yi https://orcid.org/0000-0002-6643-8326
Bordia, Sonal
Li, Shouguo
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03675737 at ClinicalTrials.govDocuments that mention this clinical trial
First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.
https://doi.org/10.1200/jco.2024.42.3_suppl.345
First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study
https://doi.org/10.1007/s12325-024-03069-4
KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations.
https://doi.org/10.1200/jco.2023.41.16_suppl.4014
Pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study.
https://doi.org/10.1200/jco.2024.42.16_suppl.4045
-
Funding
Funding for this research was provided by:
Funding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
- License Information
-
More Information
Article History
Received: 27 August 2024
Accepted: 8 November 2024
First Online: 1 March 2025
Declarations
:
: Yixiang Mao is an employee of MSD China, Shanghai, China, and owns stock in Merck & Co., Inc., Rahway, NJ, USA. Run Guo and Yi Zuo are employees of MSD China, Beijing, China. Sonal Bordia is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, and owns stock in Merck & Co., Inc., Rahway, NJ, USA. Shukui Qin, Yuxian Bai, Jin Li, Hongming Pan, Suxia Luo, Yanli Qu, Feng Ye, Lin Yang, Tianshu Liu, Wei Li, Xi Chen, Jianwei Yang, Jieer Ying, Xiaoyan Lin, Lin Zhao, Xinjun Liang, and Shouguo Li report no conflict of interest.
: The study protocol and amendments, including changes that affected study design, were approved by the appropriate local or national ethics committee at each participating center. All participants provided written informed consent. The study was done in accordance with the Good Clinical Practice requirements outlined by the International Council on Harmonization, the ethical principles of the Declaration of Helsinki, and all local regulations. Institutional review boards or independent ethics committees at each site approved the protocol. The full list of participating sites and ethics committees can be found in the Supplementary Materials Table S5.
